Pressure BioSciences Inc. (OTCQB: PBIO), a leader in the development and sale of pressure-based instruments, consumables and related services for the global life sciences industry, today announced that its president and CEO, Richard T. Schumacher, was featured on the Uptick Newswire Stock Day Podcast with Everett Jolly. During the interview, Schumacher discussed the company’s recently-announced collaboration with NutraFuels Inc., the commercial launch of its BioPharmaceuticals contract services business and the publication of over 20 scientific papers on PBIO’s unique pressure-based products throughout 2018.
“We are a time-tested company with patents, products, a tremendous customer base, an expanding market, and increasing sales,” Schumacher stated in the interview. “We have struggled a bit over the past few years for a number of different reasons, but we believe we are past that now and on the road to success. Our three pressure-based technology platforms have been vetted by key opinion leaders globally, we have a number of leading scientists in the world who are using our various products, and we expect increased revenue in 2019 from our two new platform technologies (Barofold and UST). We believe that PBIO shareholders have much to be excited about going forward.”
To listen to the full interview, visit http://ibn.fm/WdJBQ
To view the full press release, visit http://ibn.fm/DU3fN
About Pressure BioSciences Inc.
Pressure BioSciences, Inc. is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). PBIO’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) the use of its recently acquired PreEMT technology from BaroFold, Inc. to allow entry into the biologics contract research services sector, and (2) the use of its recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information, visit the company’s website at www.PressureBiosciences.com
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
